Visual Hallucinations and Amyloid Deposition in Parkinson’s Disease Dementia: A Case Report

키워드

참고문헌 (46)

1. Aarsland D, "A systematic review of prevalence studies of dementia in Parkinson’s disease", Mov Disord, 20, pp.1255~1263 (2005)
2. Buter T, "Dementia and survival in Parkinson disease : a 12-year population study", Neurology, 70, pp.1017~1022 (2008)
3. Aarsland D, "Prevalence and characteristics of dementia in Parkinson disease : an 8-year prospective study", Arch Neurol, 60, pp.387~392 (2003)
4. Williams-Gray CH, "The distinct cognitive syndromes of Parkinson’s disease : 5year follow-up of the CamPaIGN cohort", Brain, 132, pp.2958~2969 (2009)
5. Fitts W, "Caregiver report of apathy predicts dementia in Parkinson’s disease", Parkinsonism Relat Disord, 21, pp.992~995 (2015)
6. Weintraub D, "Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease", Brain, 135, pp.170~180 (2012)
7. Compta Y, "Lewy-and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important?", Brain, 134, pp.1493~1505 (2011)
8. de Lau LM, "Prognosis of parkinson disease : risk of dementia and mortality : the Rotterdam study", Arch Neurol, 62, pp.1265~1269 (2005)
9. Hughes CP, "A new clinical scale for the staging of dementia", Br J Psychiatry, 140, pp.566~572 (1982)
10. O’Bryant SE, "Staging dementia using clinical dementia rating scale sum of boxes scores : a Texas Alzheimer’s research consortium study", Arch Neurol, 65, pp.1091~1095 (2008)
11. Cummings JL, "The neuropsychiatric inventory : comprehensive assessment of psychopathology in dementia", Neurology, 44, pp.2308~2314 (1994)
12. 구형모, "일상활동평가-복합(Seoul-Instrumental Activities of Daily Living ; S-IADL)의 신뢰도 및 타당도 연구", 신경정신의학, 43(2), pp.189~199 (2004), 대한신경정신의학회
13. Lee DY, "A normative study of the CERAD neuropsychological assessment battery in the Korean elderly", J Int Neuropsychol Soc, 10, pp.72~81 (2004)
14. Lee JH, "Korean version of the consortium to establish a registry for Alzheimer’s disease assessment packet(CERAD-K) : Clinical and neuropsychological assessment batteries", Neurobiol Aging, 21, pp.32~ (2000)
15. Scheltens P, "Atrophy of medial temporal lobes on MRI in"probable"Alzheimer’s disease and normal ageing : diagnostic value and neuropsychological correlates", J Neurol Neurosurg Psychiatry, 55, pp.967~972 (1992)
16. Wahlund L, "A new rating scale for age-related white matter changes applicable to MRI and CT", Stroke, 32, pp.1318~1322 (2001)
17. Scheltens P, "Qualitative assessment of cerebral atrophy on MRI : inter-and intra-observer reproducibility in dementia and normal aging", Eur Neurol, 37, pp.95~99 (1997)
18. McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
19. Johnson KA, "Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association", J Nucl Med, 54, pp.476~490 (2013)
20. Sabri O, "Beta-amyloid imaging with florbetaben", Clin Transl Imaging, 3, pp.13~26 (2015)
21. Winslow AR, "Convergence of pathology in dementia with Lewy bodies and Alzheimer’s disease : a role for the novel interaction of alpha-synuclein and presenilin 1 in disease", Brain, 137, pp.1958~1970 (2014)
22. Xie A, "Shared mechanisms of neurodegeneration in Alzheimer’s disease and Parkinson’s disease", Biomed Res Int, 2014, pp.648740~ (2014)
23. Metzler-Baddeley C, "A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer’s disease and Parkinson’s disease with dementia", Cortex, 43, pp.583~600 (2007)
24. PIB positron emission tomography, "J Neurol Neurosurg Psychiatry", 2008, 1331~1338
25. Gomperts SN, "Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia", Neurology, 80, pp.85~91 (2013)
26. Svenningsson P, "Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment", Lancet Neurol, 11, pp.697~707 (2012)
27. Compta Y, "The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson’s disease progression and related dementia", Neurodegener Dis, 13, pp.154~156 (2014)
28. Aarsland D, "The rate of cognitive decline in Parkinson disease", Arch Neurol, 61, pp.1906~1911 (2004)
29. Fénelon G, "Hallucinations in Parkinson’s disease. Prevalence, phenomenology, and risk factors", Brain, 123, pp.733~745 (2000)
30. Factor SA, "Cognitive correlates of hallucinations and delusions in Parkinson’s disease", J Neurol Sci, 347, pp.316~321 (2014)
31. Shine JM, "The role of dysfunctional attentional control networks in visual misperceptions in Parkinson’s disease", Human Brain Mapp, 35, pp.2206~2219 (2014)
32. Barnes J, "Reality monitoring and visual hallucinations in Parkinson’s disease", Neuropsychologia, 41, pp.565~574 (2003)
33. Muller AJ, "Visual hallucinations in Parkinson’s disease : theoretical models", Mov Disord, 29, pp.1591~1598 (2014)
34. Ondo WG, "Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease", Mov Disord, 20, pp.958~963 (2005)
35. Rabey JM, "Effect of quetiapine in psychotic Parkinson’s disease patients : a double-blind labeled study of 3 months’ duration", Mov Disord, 22, pp.313~318 (2007)
36. Morgante L, "Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis", Clin Neuropharmacol, 27, pp.153~156 (2004)
37. Broadstock M, "Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease", Expert Rev Clin Pharmacol, 7, pp.779~786 (2014)
38. Nagata T, "A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease", Int Psychogeriatr, 25, pp.1199~1201 (2013)
39. Tagai K, "Mirtazapine improves visual hallucinations in Parkinson’s disease : a case report", Psychogeriatrics, 13, pp.103~107 (2013)
40. Nishioka K, "Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with refractory psychiatric symptoms", J Neural Transm, 121, pp.1405~1410 (2014)
41. Boroojerdi B, "Reduction of human visual cortex excitability using 1-Hz transcranial magnetic stimulation", Neurology, 54, pp.1529~1531 (2000)
42. Merabet LB, "Suppression of complex visual hallucinatory experiences by occipital transcranial magnetic stimulation : a case report", Neurocase, 9, pp.436~440 (2003)
43. Burn D, "Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease", Mov Disord, 21, pp.1899~1907 (2006)
44. Bullock R, "Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease : a case series", Curr Med Res Opin, 18, pp.258~264 (2002)
45. Cummings JL, "Cholinesterase inhibitors : a new class of psychotropic compounds", Am J Psychiatry, 157, pp.4~15 (2000)
46. Blom JD, "Musical hallucinations treated with acetylcholinesterase inhibitors", Front Psychiatry, 6, pp.46~ (2015)

관련 논문AI추천